Despite higher earnings, Wall St. wary of healthcare

Amy Baxter | | Health Exec | Policy & Regulations

While many of the largest healthcare companies have seen rising revenues and record profits at the start of 2019, stock prices aren’t reflecting their successes, Axios reported.

The discrepancy underscores that investors are wary about the healthcare sector as the Affordable Care Act is under dispute in court and as some lawmakers continue to push for a single-payer healthcare system. In fact, the rising support for Medicare for all may have soured healthcare on Wall St., according to Axios.

Another major factor in the space is the ongoing debate around rebates, which the Trump administration has considered eliminating from pharmacy benefit managers. That uncertainty has created further turmoil across healthcare stocks.

See the full story below:

Wall Street has kind of soured on health care

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

More than 1,000 hospitals earn $700M opioid crisis judgment
VA planning 83,000 layoffs as part of restructuring
HIMSS survey report: Beware insider threats to cybersecurity involving AI
HHS spokesperson abruptly resigns, reportedly after clash with RFK
Hospital faces $3.5M settlement after sharing patient data with Facebook
Philips pulls endovascular devices from market after safety issues prompt Class I recall

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.